Blood Proteins

Name
Blood Proteins
Accession Number
DBCAT000019
Description

Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.

Drugs
DrugDrug Description
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
Antihemophilic factor, human recombinantA form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.
Human immunoglobulin GA purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
Coagulation factor VIIa Recombinant HumanA form of recombinant human coagulation Factor VII used to treat hemophilia A and B.
OmalizumabA monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
Indium In-111 satumomab pendetideFor diagnosis of extrahepatic malignant cancers
Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
Albumin humanA purified form of human serum albumin used to replace lost albumin in patients with hypoalbuminemia, to treat hypovolemia and ascites, and as a part of some diagnostic imaging kits.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
MuromonabA monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Ibritumomab tiuxetanA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
TositumomabA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Capromab pendetideA monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Antithymocyte immunoglobulin (rabbit)A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
BecaplerminA recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
NatalizumabA monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
Technetium Tc-99m arcitumomabFor imaging colorectal tumors
EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
MecaserminA recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH.
GaliximabInvestigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
PexelizumabFor the treatment of inflammation during cardiac surgery.
AfelimomabInvestigated for use/treatment in sepsis and septicemia.
EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
BectumomabInvestigated for use/treatment in lymphoma (non-hodgkin's).
OregovomabInvestigated for use/treatment in ovarian cancer.
IGN311Intended for the treatment of various forms of cancer.
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
CR002Investigated for use/treatment in nephropathy.
RozrolimupabInvestigated for use/treatment in thrombocytopenia.
Hepatitis B immune globulinAn injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection.
ObiltoxaximabA monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
XTL-001Investigated for use/treatment in hepatitis (viral, B).
NAV 1800Investigated for use/treatment in colorectal cancer and solid tumors.
BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
AMG 108Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
IratumumabInvestigated for use/treatment in lymphoma (unspecified).
EnokizumabInvestigated for use/treatment in asthma.
RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
FarletuzumabInvestigated for use/treatment in ovarian cancer.
VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
TNX-901Investigated for use/treatment in allergic reaction.
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
RI 624Investigated for use/treatment in pain (acute or chronic).
MYO-029Investigated for use/treatment in muscular dystrophy.
LeronlimabA humanized monoclonal antibody being investigated
Glembatumumab vedotinInvestigated for use/treatment in melanoma.
OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
IPH 2101Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
TB-402Investigated for use/treatment in atrial fibrillation and thrombosis.
CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
IMC-1C11Investigated for use/treatment in cancer/tumors (unspecified).
EldelumabInvestigated for use/treatment in ulcerative colitis.
LumiliximabInvestigated for use/treatment in asthma and leukemia (lymphoid).
CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
NimotuzumabAn EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.
ClenoliximabInvestigated for use/treatment in rheumatoid arthritis.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
BIIB015Investigated for use/treatment in solid tumors.
MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
AVE9633Investigated for use/treatment in leukemia (myeloid).
CarotuximabInvestigated for use/treatment in solid tumors.
XmAb 2513Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
Coltuximab ravtansineInvestigated for use/treatment in lymphoma (non-hodgkin's).
LucatumumabInvestigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
SibrotuzumabInvestigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
LerdelimumabInvestigated for use/treatment in glaucoma and cataracts.
LexatumumabInvestigated for use/treatment in cancer/tumors (unspecified).
ReslizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
TeplizumabA humanized IgG1κ Fc-nonbinding anti-CD3 monoclonal antibody currently under development as an immune therapy to prolong progression to type 1 diabetes in high-risk patients.
CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
MepolizumabA fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
GolimumabA TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
BelimumabA B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat systemic lupus erythematosus and active lupus nephritis as an add-on therapy.
RaxibacumabA monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
SecukinumabAn immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
BlinatumomabAn antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Asfotase alfaAn enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
AlirocumabA PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
EvolocumabA PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis.
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
Antithrombin III humanAn alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
Human varicella-zoster immune globulinA solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
ConatumumabConatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
TabalumabTabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
FiclatuzumabFiclatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
FigitumumabFigitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
BapineuzumabBapineuzumab has been investigated for the treatment of Alzheimer's Disease.
OnartuzumabOnartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
SolanezumabSolanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
TremelimumabTremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part...
BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
SirukumabSirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
GuselkumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DalotuzumabDalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
EmibetuzumabEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
LigelizumabAn IgE-directed monoclonal antibody under investigation for the treatment of chronic spontaneous urticaria (CSU).
SeribantumabSeribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
LandogrozumabLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
RomosozumabA monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
CrenezumabCrenezumab has been used in trials studying the treatment of Alzheimer's Disease.
RilotumumabRilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
AnifrolumabA monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus.
OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
GantenerumabA fully human IgG1κ monoclonal antibody with specificity for amyloid-beta oligomers and fibrils under investigation for the treatment of Alzheimer's disease.
VisilizumabVisilizumab has been investigated for the treatment of Ulcerative Colitis.
Lorvotuzumab mertansineLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
PatritumabPatritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
FulranumabFulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
TarextumabTarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
GevokizumabGevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
DuligotuzumabDuligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
DupilumabA monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
TralokinumabA monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.
EtrolizumabA humanized IgG1κ anti-β7 integrin subunit monoclonal antibody under investigation for use in ulcerative colitis and Crohn's disease.
GanitumabGanitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
EtaracizumabEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Polatuzumab vedotinA CD79b antibody conjugate indicated to treat relapsed or refractory B-cell lymphoma.
InclacumabInclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
CixutumumabCixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant...
AscrinvacumabAscrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
AducanumabA monoclonal antibody indicated in the treatment of Alzheimer's disease.
TanezumabTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
DusigitumabDusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
FresolimumabFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
BococizumabBococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
Mirvetuximab SoravtansineMirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.
InebilizumabA humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD).
MavrilimumabMavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
BlosozumabBlosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
BimagrumabBimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
TovetumabTovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
IbalizumabA CD4-specific antibody used to treat HIV infections.
IntetumumabIntetumumab has been used in trials studying the treatment of Melanoma.
CarlumabCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
DemcizumabDemcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
AbituzumabAbituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Naptumomab estafenatoxNaptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
CrotedumabCrotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
ConcizumabConcizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
DepatuxizumabDepatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
RontalizumabRontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
AmatuximabAmatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
ClazakizumabClazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
OzanezumabOzanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
MilatuzumabMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
RobatumumabRobatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.
RacotumomabRacotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
OlokizumabA humanized anti-IL-6 IgG4κ antibody under investigation for use in autoimmune conditions including rheumatoid arthritis.
EdrecolomabNot Annotated
NebacumabNot Annotated
Human cytomegalovirus immune globulinA solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants.
EmicizumabAn antibody against Factor IXa and Factor X used to treat hemophilia A.
SulesomabMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
BesilesomabA monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
TildrakizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
ErenumabA calcitonin-gene related peptide antagonist used to prevent migraines.
FremanezumabA humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
FanolesomabAn anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
LebrikizumabLebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
BenralizumabA monoclonal antibody used to treat eosinophilic asthma.
ZalutumumabZalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
PlozalizumabPlozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
SifalimumabSifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,...
Turoctocog alfa pegolTuroctocog alfa pegol is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to...
GirentuximabInvestigated for use/treatment in gall bladder cancer and renal cell carcinoma.
RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease in adults.
Anetumab ravtansineAnetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
IsatuximabA chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
IcrucumabIcrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
EmactuzumabEmactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
RefanezumabRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
PamrevlumabPamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
PateclizumabPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
ApomabApomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
AbrilumabAbrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
TigatuzumabTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
UtomilumabUtomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
ZolbetuximabZolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).
PonezumabPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
AsunerceptAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
SuvratoxumabSuvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
MitazalimabMitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).
BleselumabBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant...
Valanafusp alfaValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
IstiratumabIstiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
PidilizumabPidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
GMA-161GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
Ladiratuzumab vedotinLadiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
TomaralimabTomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
VesencumabVesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Pinatuzumab vedotinPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
Lulizumab pegolLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Lorukafusp alfaLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Naratuximab emtansineNaratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
CT-011Investigated for use/treatment in cancer/tumors (unspecified).
SonepcizumabInvestigated for use/treatment in solid tumors.
Thrombin alfaA platelet activating factor used to treat minor bleeding.
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
Depatuxizumab mafodotinNo approved indication.
UblituximabA low-fucose monoclonal anti-CD20 antibody with enhanced ADCC being investigated for use in leukemia, lymphoma, and autoimmune conditions such as multiple sclerosis.
Vadastuximab talirineVadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
VarlilumabVarlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
UrelumabUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody...
SimtuzumabSimtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
FasinumabA monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.
GS-5745GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
VanucizumabVanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
Labetuzumab govitecanLabetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
EnsituximabEnsituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer.
FezakinumabFezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
Indusatumab vedotinIndusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
LumretuzumabLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
EcromeximabEcromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
BimekizumabAn anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.
Rovalpituzumab tesirineRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
NamilumabNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
TregalizumabTregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
BezlotoxumabA monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
BurosumabA fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
LecanemabLecanemab is an experimental drug that is currently in clinical trials for the treament of Alzheimer's disease.
CemiplimabA programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
SetrusumabSetrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
CodrituzumabCodrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
XentuzumabXentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
ParsatuzumabParsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
RozanolixizumabRozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
OpicinumabOpicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Trastuzumab deruxtecanAn antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
MargetuximabAn Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
GremubamabGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
TafasitamabA CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
FrovocimabFrovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
TezepelumabA human monoclonal IgG2λ thymic stromal lymphopoietin (TSLP)-blocking antibody for add-on maintenance therapy in severe asthma.
Telisotuzumab vedotinTelisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
NemolizumabNemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
GedivumabGedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
Sofituzumab vedotinSofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
ZenocutuzumabZenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
InolimomabInolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry...
EptinezumabA monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
TheralizumabTheralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia...
Belantamab mafodotinAn anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
PentaglobinPentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. It is comprised of immunoglobulin G (IgG) (https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched...
AbagovomabAbagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
Dapirolizumab pegolDapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
EfungumabEfungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
ForalumabForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Indatuximab ravtansineIndatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
ItolizumabItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
MagrolimabMagrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
OlinvacimabOlinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
OntuxizumabOntuxizumab is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
OtlertuzumabOtlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Anti-SARS-CoV-2 immunoglobulinHyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains...
ActoxumabActoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
ToralizumabToralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
BirtamimabBirtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
VolagidemabVolagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
FibrinNot Annotated
Antilymphocyte immunoglobulin (horse)A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
Tetanus immune globulin, humanA solution of antibodies used to prevent tetanus after an injury.
SotaterceptSotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.
Digoxin Immune Fab (Ovine)An antibody binding fragment which binds digoxin molecules which is used as an antidote to digoxin overdose.
Anthrax immune globulin humanAn immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents.
EmapalumabAn interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
BermekimabBermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
CrizanlizumabA monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
SatralizumabA subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
OdesivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
MaftivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
AtoltivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
BamlanivimabA neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.
NaxitamabA GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
AnsuvimabA fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease.
Human Rho(D) immune globulinA solution of antibodies used to prevent isoimmunization of Rho(D) negative patients exposed to Rho(D) positive blood in pregnancy or transfusion.
BentracimabBentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).
Moxetumomab pasudotoxA CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
Cantuzumab ravtansineInvestigated for use/treatment in gastric cancer.
Cergutuzumab amunaleukinCergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors).
GosuranemabGosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
Lifastuzumab vedotinLifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
Trastuzumab duocarmazineTrastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Tucotuzumab celmoleukinTucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...
Vorsetuzumab mafodotinVorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
AnrukinzumabAnrukinzumab has been used in trials studying the diagnostic of Asthma.
BemarituzumabBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
BrontictuzumabBrontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.
CabiralizumabCabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
CusatuzumabA CD70-directed monoclonal antibody under investigation for the treatment of hematological malignancies.
DezamizumabDezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
DomagrozumabDomagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
DostarlimabAn anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.
EnoblituzumabEnoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).
FaricimabAn IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema.
FlotetuzumabFlotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).
ImgatuzumabImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
LacnotuzumabLacnotuzumab is under investigation in clinical trial NCT01643850 (MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)).
LutikizumabLutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
MirikizumabMirikizumab is under investigation in clinical trial NCT03053622 (A Study of Mirikizumab (LY3074828) Injection in Healthy Participants).
MonalizumabMonalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
MosunetuzumabA humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma.
OlendalizumabOlendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
OzoralizumabOzoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis.
PascolizumabInvestigated for use/treatment in asthma.
VonlerolizumabVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who...
PrasinezumabPrasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
QuilizumabQuilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).
RavagalimabRavagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis...
RuplizumabInvestigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.
SamalizumabSamalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
SpartalizumabSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
TalacotuzumabTalacotuzumab is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
TefibazumabTefibazumab is under investigation in clinical trial NCT00198289 (Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs).
TelisotuzumabTelisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).
TibulizumabTibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).
TislelizumabTislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
TomuzotuximabTomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).
VatelizumabVatelizumab has been used in trials studying the treatment of Ulcerative Colitis.
VopratelimabVopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).
VunakizumabVunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
AmivantamabAn EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
PlasminogenPlasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
SotrovimabA monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
RegdanvimabA monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19.
ImdevimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
CasirivimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
CilgavimabAn extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
TixagevimabAn extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
OrdesekimabOrdesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
HemoglobinAn iron-containing protein found in all red blood cells (RBCs) for proper binding of oxygen and transport throughout the body, included in blood transfusions in severe hemorrhage.
Protein S humanA medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
Plasma protein fraction (human)A plasma protein solution used to treat coagulation factor deficiencies, reverse anticoagulant effects, and shock from a loss of plasma fluids, and is also used in plasma exchange procedures.
PRM-151PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
EflapegrastimEflapegrastim is under investigation in clinical trial NCT02953340 (Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide...
RemtolumabRemtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
AbataceptA disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
LanoteplaseInvestigated for use/treatment in myocardial infarction.
OtilimabInvestigated for use/treatment in inflammatory disorders (unspecified).
AtibuclimabInvestigated for use/treatment in sepsis and septicemia and pneumonia.
AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
BelataceptA selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Turoctocog alfaAn antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).
Fibrinogen humanA hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Conestat alfaA recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.
Antihemophilic factor (recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)...
Technetium Tc-99m nofetumomab merpentanTc-99m nm is one of the technetium-labeled antibodies and it is indicated for the detection of small-cell lung cancer. The small cell lung cancer is a syndrome characterized by the...
ThrombinA coagulation factor used to stop bleeding during surgery.
ProthrombinA coagulation factor used for emergency reversal of vitamin K antagonist therapy.
Factor IX Complex (Human)A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy.
Rusalatide acetateChrysalin has been used in trials studying the treatment of Radius Fracture.
TesidolumabTesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.
UlocuplumabUlocuplumab is under investigation in Solid Tumor.
Tetulomab tetraxetan Lu-177Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
FletikumabFletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).
Vatreptacog alfaVatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
NavicixizumabNavicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
FirategrastFirategrast has been used in trials studying the treatment of Multiple Sclerosis.
Factor XIII (human)A purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency.
AlbusomatropinAlbusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency.
Von Willebrand factor humanA blood clotting factor used to manage bleeding episodes in von Willebrand disease and hemophilia A,.
Coagulation factor X humanA coagulation factor used to treat Factor X deficiency to control bleeding.
Coagulation factor VII humanA coagulation factor used to treat bleeding disorders such as hemophilia and Glanzmann's thrombasthenia.
Anti-inhibitor coagulant complexA medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B.
Coagulation Factor IX HumanA coagulation factor used to treat hemophilia B or factor IX hemophilia.
Antihemophilic factor humanA Factor VIII replacement therapy used to treat hemophilia A.
KallidinogenaseNot Annotated
Trenonacog alfaHuman coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells.
SaruplaseNot Annotated
Hemoglobin crosfumarilHemoglobin in which the alpha-subunit are cross-linked intramolecularly.
Albutrepenonacog alfaA recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.
Nonacog beta pegolA recombinant coagulation Factor IX derivative used to treat hemophilia B.
Moroctocog alfaA recombinant Factor VIII used to treat hemophilia A to control bleeding.
Insulin-like growth factor IIThe insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth...
Beroctocog alfaBeroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in...
Andexanet alfaA recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban.
VofatamabVofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).
OsocimabOsocimab is under investigation in clinical trial NCT03276143 (Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty).
SelicrelumabSelicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
SutimlimabA monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease.
ToripalimabToripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
LenzilumabLenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).
IscalimabIscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
FutuximabFutuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors).
EdratideEdratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Marzeptacog alfa (activated)Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
GimsilumabGimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).
OntamalimabOntamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
OrilanolimabOrilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Coagulation factor XIaCoagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).
ElgemtumabElgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
SpesolimabSpesolimab is under investigation in clinical trial NCT03886246 (A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130).
TemelimabTemelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).
ZilucoplanZilucoplan is under investigation in clinical trial NCT04225871 (Open-label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis).
Anti-SARS-CoV-2 REGN-COV2Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
SintilimabNot Annotated
EnvafolimabNot Annotated
AZD7442AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...
XAV-19XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a...
EtesevimabEtesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral...
Rurioctocog alfa pegolA pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A.
GlenzocimabNot Annotated
GontivimabGontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
ItepekimabItepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).
Loncastuximab tesirineAn antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
NirsevimabNirsevimab is under investigation in clinical trial NCT03959488 (A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(rsv) Lower Respiratory Track Infection (LRTI)...
GlofitamabGlofitamab is under investigation in clinical trial NCT04408638 (A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants...
FelzartamabFelzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
AstegolimabAstegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
LevilimabLevilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
AxatilimabAxatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
ZansecimabZansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
AvdoralimabAvdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
VilobelimabVilobelimab is under investigation in clinical trial NCT03895801 (Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis).
NarsoplimabAn anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
MeplazumabMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
IanalumabIanalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
BudigalimabBudigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV...
AbelacimabAbelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).
TengonerminTengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
LirentelimabLirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
EnibarcimabEnibarcimab is under investigation in clinical trial NCT03989531 (Adrecizumab in Cardiogenic Shock).
Tisotumab vedotinA tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
BebtelovimabA human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19.
Drugs & Drug Targets
DrugTargetType
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlteplaseUrokinase plasminogen activator surface receptortarget
AlteplaseFibrinogen alpha chaintarget
AlteplasePlasminogentarget
AlteplasePlasminogen activator inhibitor 1target
UrokinaseUrokinase plasminogen activator surface receptortarget
UrokinasePlasminogentarget
UrokinasePlasminogen activator inhibitor 2target
UrokinasePlasminogen activator inhibitor 1target
UrokinasePlasma serine protease inhibitortarget
UrokinaseNidogen-1target
UrokinaseLow-density lipoprotein receptor-related protein 2target
UrokinaseSuppressor of tumorigenicity 14 proteintarget
UrokinaseMacrophage metalloelastaseenzyme
ReteplaseFibrinogen alpha chaintarget
ReteplasePlasminogentarget
ReteplasePlasminogen activator inhibitor 1target
Antihemophilic factor, human recombinantCoagulation factor Xtarget
Antihemophilic factor, human recombinantPhytanoyl-CoA dioxygenase, peroxisomaltarget
Antihemophilic factor, human recombinantCoagulation factor IXtarget
Antihemophilic factor, human recombinantAsialoglycoprotein receptor 2target
Antihemophilic factor, human recombinant78 kDa glucose-regulated proteintarget
Antihemophilic factor, human recombinantCalreticulintarget
Antihemophilic factor, human recombinantCalnexintarget
Antihemophilic factor, human recombinantProtein ERGIC-53target
Antihemophilic factor, human recombinantProlow-density lipoprotein receptor-related protein 1target
Antihemophilic factor, human recombinantMultiple coagulation factor deficiency protein 2target
Antihemophilic factor, human recombinantvon Willebrand factortarget
Antihemophilic factor, human recombinantProthrombinenzyme
Antihemophilic factor, human recombinantVitamin K-dependent protein Cenzyme
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor Itarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-atarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor IBtarget
Human immunoglobulin GComplement C3target
Human immunoglobulin GComplement C4-Atarget
Human immunoglobulin GComplement C4-Btarget
Human immunoglobulin GComplement C5target
Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
Coagulation factor VIIa Recombinant HumanTissue factortarget
Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
AdalimumabTumor necrosis factortarget
AbciximabIntegrin beta-3target
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AbciximabIntegrin alpha-IIbtarget
AbciximabVitronectintarget
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
Indium In-111 satumomab pendetideTumor-associated glycoprotein 72 (TAG-72)target
Alpha-1-proteinase inhibitorNeutrophil elastasetarget
Albumin humanNitric oxidetarget
InfliximabTumor necrosis factortarget
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
RituximabB-lymphocyte antigen CD20target
BasiliximabInterleukin-2 receptor subunit alphatarget
BasiliximabInterleukin-2 receptor subunit betatarget
MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
MuromonabT-cell surface glycoprotein CD3 delta chaintarget
MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
Ibritumomab tiuxetanB-lymphocyte antigen CD20target
TositumomabB-lymphocyte antigen CD20target
TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabCAMPATH-1 antigentarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Capromab pendetideGlutamate carboxypeptidase 2target
EfalizumabIntegrin alpha-Ltarget
EfalizumabIntegrin alpha-Xtarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
BecaplerminPlatelet-derived growth factor receptor betatarget
BecaplerminAlpha-2-macroglobulintarget
BecaplerminPlatelet-derived growth factor receptor alphatarget
NatalizumabIntegrin alpha-4target
NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
NatalizumabIntercellular adhesion molecule 1target
PalivizumabFusion glycoprotein F0target
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
PalivizumabComplement C1r subcomponenttarget
PalivizumabComplement C1q subcomponent subunit Atarget
PalivizumabComplement C1q subcomponent subunit Btarget
PalivizumabComplement C1q subcomponent subunit Ctarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabInterleukin-2 receptor subunit alphatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DaclizumabComplement C1r subcomponenttarget
DaclizumabComplement C1q subcomponent subunit Atarget
DaclizumabComplement C1q subcomponent subunit Btarget
DaclizumabComplement C1q subcomponent subunit Ctarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaclizumabInterleukin-2 receptor subunit betatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Technetium Tc-99m arcitumomabCarcinoembryonic antigen-related cell adhesion molecule 1target
EculizumabComplement C5target
PanitumumabEpidermal growth factor receptortarget
RanibizumabVascular endothelial growth factor Atarget
MecaserminInsulin-like growth factor 1 receptortarget
MecaserminInsulin-like growth factor-binding protein 3target
MecaserminInsulin receptortarget
MecaserminCation-independent mannose-6-phosphate receptortarget
MecaserminInsulin-like growth factor-binding protein 3carrier
MecaserminInsulin-like growth factor-binding protein complex acid labile subunitcarrier
MecaserminInsulin-like growth factor-binding protein 1carrier
MecaserminInsulin-like growth factor-binding protein 2carrier
MecaserminInsulin-like growth factor-binding protein 4carrier
MecaserminInsulin-like growth factor-binding protein 5carrier
MecaserminInsulin-like growth factor-binding protein 6carrier
GaliximabT-lymphocyte activation antigen CD80target
AfelimomabTumor necrosis factortarget
EpratuzumabB-cell receptor CD22target
OregovomabMucin-16target
IGN311Epidermal growth factor receptortarget
IGN311Receptor tyrosine-protein kinase erbB-2target
LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
MatuzumabEpidermal growth factor receptortarget
FontolizumabInterferon gammatarget
CR002Platelet-derived growth factor Dtarget
RozrolimupabRhesus blood group D antigentarget
Hepatitis B immune globulinHBsAgtarget
BriakinumabInterleukin-12 subunit betatarget
BriakinumabInterleukin-23 subunit alphatarget
IratumumabTumor necrosis factor receptor superfamily member 8target
RamucirumabVascular endothelial growth factor receptor 2target
FarletuzumabFolate receptor alphatarget
UstekinumabInterleukin-12 subunit betatarget
UstekinumabInterleukin-23target
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
PRO-542Free fatty acid receptor 4target
TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
RI 624Beta-nerve growth factortarget
MYO-029Growth/differentiation factor 8target
LeronlimabC-C chemokine receptor type 5target
Glembatumumab vedotinTransmembrane glycoprotein NMBtarget
OlaratumabPlatelet-derived growth factor receptor alphatarget
TB-402Coagulation factor VIIItarget
Caplacizumabvon Willebrand factortarget
IMC-1C11Vascular endothelial growth factor receptor 1target
IMC-1C11Vascular endothelial growth factor receptor 2target
IMC-1C11Vascular endothelial growth factor receptor 3target
EldelumabC-X-C motif chemokine 10target
LumiliximabLow affinity immunoglobulin epsilon Fc receptortarget
CanakinumabInterleukin-1 betatarget
IpilimumabCytotoxic T-lymphocyte protein 4target
ClenoliximabT-cell surface glycoprotein CD4target
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
ElotuzumabSLAM family member 7target
AVE9633Myeloid cell surface antigen CD33target
AVE9633Cytochrome P450 3A4enzyme
CarotuximabEndoglintarget
XmAb 2513Tumor necrosis factor receptor superfamily member 8target
Coltuximab ravtansineB-lymphocyte antigen CD19target
Coltuximab ravtansineCytochrome P450 3A4enzyme
LucatumumabTumor necrosis factor receptor superfamily member 5target
PertuzumabReceptor tyrosine-protein kinase erbB-2target
SiplizumabT-cell surface antigen CD2target
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
SibrotuzumabSeprasetarget
BivatuzumabCD44 antigentarget
LexatumumabTumor necrosis factor receptor superfamily member 10Btarget
ReslizumabInterleukin-5target
TeplizumabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabEpithelial cell adhesion moleculetarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
MepolizumabInterleukin-5target
DenosumabTumor necrosis factor ligand superfamily member 11target
OfatumumabB-lymphocyte antigen CD20target
GolimumabTumor necrosis factortarget
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
BelimumabTumor necrosis factor ligand superfamily member 13Btarget
RaxibacumabProtective antigentarget
ObinutuzumabB-lymphocyte antigen CD20target
SecukinumabInterleukin-17Atarget
VedolizumabIntegrin alpha-4target
VedolizumabIntegrin beta-7target
NivolumabProgrammed cell death protein 1target
NivolumabProgrammed cell death 1 ligand 1target
SiltuximabInterleukin-6target
SiltuximabCytochrome P450 3A4enzyme
PembrolizumabProgrammed cell death protein 1target
PembrolizumabProgrammed cell death 1 ligand 1target
DulaglutideGlucagon-like peptide 1 receptortarget
BlinatumomabB-lymphocyte antigen CD19target
BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DinutuximabGD2 disialogangliosidetarget
Asfotase alfaPyrophosphatetarget
AlirocumabProprotein convertase subtilisin/kexin type 9target
EvolocumabProprotein convertase subtilisin/kexin type 9target
DaratumumabADP-ribosyl cyclase 1target
NecitumumabEpidermal growth factor receptortarget
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
IxekizumabInterleukin-17Atarget
AtezolizumabProgrammed cell death 1 ligand 1target
AtezolizumabProgrammed cell death protein 1target
Antithrombin III humanAntithrombin-IIItarget
DurvalumabProgrammed cell death 1 ligand 1target
DurvalumabProgrammed cell death protein 1target
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
TremelimumabCytotoxic T-lymphocyte protein 4target
GuselkumabInterleukin-23 subunit alphatarget
DalotuzumabInsulin-like growth factor 1 receptortarget
LigelizumabImmunoglobulin heavy constant epsilontarget
RomosozumabSclerostintarget
AvelumabProgrammed cell death 1 ligand 1target
AvelumabProgrammed cell death protein 1target
AnifrolumabInterferon alpha/beta receptor 1target
OcrelizumabB-lymphocyte antigen CD20target
GantenerumabAmyloid beta A4 proteintarget
Lorvotuzumab mertansineCytochrome P450 3A4enzyme
GevokizumabInterleukin-1 betatarget
DupilumabInterleukin-4 receptor subunit alphatarget
DupilumabInterleukin-13target
DupilumabInterleukin-4target
TralokinumabInterleukin-13target
EtrolizumabIntegrin beta-7target
Polatuzumab vedotinCytochrome P450 3A4enzyme
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintransporter
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
CixutumumabInsulin-like growth factor 1 receptortarget
AducanumabAmyloid beta A4 proteintarget
Mirvetuximab SoravtansineCytochrome P450 3A4enzyme
InebilizumabB-lymphocyte antigen CD19target
DacetuzumabTumor necrosis factor receptor superfamily member 5target
IbalizumabT-cell surface glycoprotein CD4target
IbalizumabC-C chemokine receptor type 5target
IbalizumabC-X-C chemokine receptor type 4target
AmatuximabMesothelintarget
Sacituzumab govitecanTumor-associated calcium signal transducer 2target
Sacituzumab govitecanDNA topoisomerase 1target
Sacituzumab govitecanFar upstream element-binding protein 1target
Sacituzumab govitecanUDP-glucuronosyltransferase 1-1enzyme
OlokizumabInterleukin-6target
EmicizumabCoagulation factor IXtarget
EmicizumabCoagulation factor Xtarget
BesilesomabCarcinoembryonic antigentarget
TildrakizumabInterleukin-23target
TildrakizumabCytochrome P450 4A11enzyme
ErenumabCalcitonin gene-related peptide type 1 receptortarget
FremanezumabCalcitonin gene-related peptide 1target
FremanezumabCalcitonin gene-related peptide 2target
MogamulizumabC-C chemokine receptor type 4target
LanadelumabPlasma kallikreintarget
LebrikizumabInterleukin-13target
LebrikizumabIL13 proteintarget
BenralizumabInterleukin-5 receptor subunit alphatarget
BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
ZalutumumabEpidermal growth factor receptortarget
PlozalizumabC-C chemokine receptor type 2target
SifalimumabInterferon alpha-2target
Turoctocog alfa pegolVitamin K-dependent protein Cenzyme
Turoctocog alfa pegolCoagulation factor Xenzyme
Turoctocog alfa pegolCoagulation factor IXtarget
Turoctocog alfa pegolCoagulation factor Xtarget
Turoctocog alfa pegolProthrombintarget
Turoctocog alfa pegolvon Willebrand factortarget
GirentuximabCarbonic anhydrase 9target
GirentuximabInterleukin-2target
RisankizumabInterleukin-23target
IsatuximabADP-ribosyl cyclase 1target
CT-011Programmed cell death protein 1target
Thrombin alfaCoagulation factor VIIItarget
Thrombin alfaCoagulation factor Vtarget
Thrombin alfaFibrinogen alpha chaintarget
Thrombin alfaFibrinogen beta chaintarget
Thrombin alfaFibrinogen gamma chaintarget
RavulizumabComplement C5target
Depatuxizumab mafodotinEpidermal growth factor receptortarget
Depatuxizumab mafodotinTubulin beta chaintarget
Depatuxizumab mafodotinB-lymphocyte antigen CD19target
UblituximabB-lymphocyte antigen CD20target
UrelumabTumor necrosis factor receptor superfamily member 9target
FasinumabBeta-nerve growth factortarget
VanucizumabAngiopoietin-2target
VanucizumabVascular endothelial growth factor Atarget
BimekizumabInterleukin-17Atarget
BimekizumabInterleukin-17Ftarget
BezlotoxumabClostridium difficile Toxin Btarget
BurosumabFibroblast growth factor 23target
GalcanezumabCalcitonin gene-related peptide 1target
GalcanezumabCalcitonin gene-related peptide 2target
CemiplimabProgrammed cell death protein 1target
CamrelizumabProgrammed cell death protein 1target
CamrelizumabProgrammed cell death 1 ligand 1target
BrolucizumabVascular endothelial growth factor Atarget
Trastuzumab deruxtecanP-glycoprotein 1transporter
Trastuzumab deruxtecanHigh affinity immunoglobulin gamma Fc receptor Itarget
Trastuzumab deruxtecanDNA topoisomerase 1target
Trastuzumab deruxtecanLysosomal alpha-glucosidaseenzyme
Trastuzumab deruxtecanDNA topoisomerase 1enzyme
Trastuzumab deruxtecanCathepsin Benzyme
Trastuzumab deruxtecanCathepsin L1enzyme
Trastuzumab deruxtecanCytochrome P450 3A4enzyme
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B1transporter
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B3transporter
Trastuzumab deruxtecanMultidrug and toxin extrusion protein 2transporter
Trastuzumab deruxtecanMultidrug resistance-associated protein 1transporter
Trastuzumab deruxtecanATP-binding cassette sub-family G member 2transporter
MargetuximabReceptor tyrosine-protein kinase erbB-2target
TafasitamabB-lymphocyte antigen CD19target
TezepelumabThymic stromal lymphopoietintarget
InolimomabInterleukin-2 receptor subunit alphatarget
EptinezumabCalcitonin gene-related peptide 1target
EptinezumabCalcitonin gene-related peptide 2target
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
Belantamab mafodotinSolute carrier organic anion transporter family member 1B1transporter
Belantamab mafodotinSolute carrier organic anion transporter family member 1B3transporter
Belantamab mafodotinMultidrug resistance-associated protein 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 2transporter
Belantamab mafodotinBile salt export pumptransporter
Belantamab mafodotinP-glycoprotein 1transporter
Belantamab mafodotinTumor necrosis factor receptor superfamily member 17target
OlinvacimabVascular endothelial growth factor receptor 2target
OtlertuzumabLeukocyte antigen CD37target
Tetanus immune globulin, humanTetanus toxintarget
SotaterceptActivin receptor type-2Atarget
Digoxin Immune Fab (Ovine)Digoxintarget
Anthrax immune globulin humanProtective antigentarget
EmapalumabInterferon gammatarget
CrizanlizumabP-selectintarget
Enfortumab vedotinCytochrome P450 3A4enzyme
Enfortumab vedotinNectin-4target
Enfortumab vedotinP-glycoprotein 1transporter
SatralizumabInterleukin-6 receptor subunit alphatarget
OdesivimabEnvelope glycoproteintarget
MaftivimabEnvelope glycoproteintarget
AtoltivimabEnvelope glycoproteintarget
BamlanivimabSpike glycoproteintarget
NaxitamabGD2 disialogangliosidetarget
AnsuvimabEnvelope glycoproteintarget
Human Rho(D) immune globulinRhesus blood group D antigentarget
Moxetumomab pasudotoxB-cell receptor CD22target
Moxetumomab pasudotoxElongation factor 2target
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
Oportuzumab monatoxEpithelial cell adhesion moleculetarget
CusatuzumabCD70 antigentarget
DostarlimabProgrammed cell death protein 1target
FaricimabVascular endothelial growth factor Atarget
FaricimabAngiopoietin-2target
MosunetuzumabB-lymphocyte antigen CD20target
MosunetuzumabT-cell surface glycoprotein CD3 epsilon chaintarget
PascolizumabInterleukin-4target
RuplizumabCD40 ligandtarget
SpartalizumabProgrammed cell death protein 1target
TislelizumabProgrammed cell death protein 1target
AmivantamabEpidermal growth factor receptortarget
AmivantamabHepatocyte growth factor receptortarget
AmivantamabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PlasminogenTissue-type plasminogen activatorenzyme
PlasminogenUrokinase-type plasminogen activatorenzyme
SotrovimabSpike glycoproteintarget
RegdanvimabSpike glycoproteintarget
ImdevimabSpike glycoproteintarget
CasirivimabSpike glycoproteintarget
CilgavimabSpike glycoproteintarget
TixagevimabSpike glycoproteintarget
Protein S humanCoagulation factor Vtarget
Protein S humanCoagulation factor Xtarget
Protein S humanVitamin K-dependent protein Ctarget
AnistreplaseFibrinogen alpha chaintarget
AnistreplasePlasminogentarget
AnistreplasePlasminogen activator inhibitor 1target
TenecteplaseUrokinase plasminogen activator surface receptortarget
TenecteplasePlasminogen activator inhibitor 1target
TenecteplaseFibrinogen alpha chaintarget
TenecteplasePlasminogen activator inhibitor 2target
TenecteplaseTetranectintarget
TenecteplaseKeratin, type II cytoskeletal 8target
TenecteplaseAnnexin A2target
TenecteplaseCalreticulintarget
TenecteplaseCalnexintarget
TenecteplaseProlow-density lipoprotein receptor-related protein 1target
TenecteplasePlasminogentarget
Drotrecogin alfaCoagulation factor VIIItarget
Drotrecogin alfaCoagulation factor Vtarget
Drotrecogin alfaPlasminogen activator inhibitor 1target
Drotrecogin alfaThrombomodulintarget
Drotrecogin alfaVitamin K-dependent protein Starget
Drotrecogin alfaProthrombintarget
Drotrecogin alfaPlatelet factor 4target
Drotrecogin alfaPlasma serine protease inhibitortarget
Drotrecogin alfaSerpin B6target
Drotrecogin alfaEndothelial protein C receptortarget
StreptokinasePlasminogentarget
StreptokinaseProteinase-activated receptor 1target
StreptokinaseCytosolic phospholipase A2enzyme
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
AbataceptCytotoxic T-lymphocyte protein 4target
DesmoteplasePlasminogentarget
LanoteplaseUrokinase plasminogen activator surface receptortarget
LanoteplaseFibrinogen alpha chaintarget
LanoteplaseKallikrein-1target
LanoteplaseLaminin subunit alpha-5target
LanoteplaseCoagulation factor Xtarget
LanoteplaseFibronectintarget
LanoteplasePlasminogen activator inhibitor 2target
LanoteplaseTetranectintarget
LanoteplaseKeratin, type II cytoskeletal 8target
LanoteplaseAnnexin A2target
LanoteplaseLaminin subunit beta-1target
LanoteplaseLaminin subunit gamma-1target
LanoteplaseLaminin subunit alpha-1target
LanoteplaseCalreticulintarget
LanoteplaseCalnexintarget
LanoteplaseProlow-density lipoprotein receptor-related protein 1target
LanoteplaseLaminin subunit alpha-3target
AtibuclimabMonocyte differentiation antigen CD14target
BelataceptT-lymphocyte activation antigen CD86target
BelataceptT-lymphocyte activation antigen CD80target
Turoctocog alfaCoagulation factor IXtarget
Turoctocog alfaCoagulation factor Xtarget
Turoctocog alfaProthrombintarget
Conestat alfaComplement C1r subcomponenttarget
Conestat alfaComplement C1s subcomponenttarget
Conestat alfaPlasma kallikreintarget
Conestat alfaCoagulation factor XIItarget
Conestat alfaProthrombintarget
Conestat alfaCoagulation factor XItarget
Conestat alfaTissue-type plasminogen activatortarget
Antihemophilic factor (recombinant), PEGylatedvon Willebrand factortarget
Antihemophilic factor (recombinant), PEGylatedvon Willebrand factorcarrier
Technetium Tc-99m nofetumomab merpentanEpithelial cell adhesion moleculetarget
Technetium Tc-99m nofetumomab merpentanB-lymphocyte antigen CD20target
ThrombinProteinase-activated receptor 1target
ThrombinProteinase-activated receptor 4target
ThrombinCoagulation factor XItarget
ThrombinCoagulation factor XIII A chaintarget
ThrombinCoagulation factor XIII B chaintarget
ThrombinFibrinogen alpha chaintarget
ThrombinFibrinogen beta chaintarget
ThrombinFibrinogen gamma chaintarget
ThrombinCoagulation factor Vtarget
ThrombinCoagulation factor VIIItarget
ProthrombinFibrinogen alpha chaintarget
ProthrombinFibrinogen beta chaintarget
ProthrombinCoagulation factor XIII A chaintarget
ProthrombinCarboxypeptidase B2target
ProthrombinCoagulation factor Xenzyme
UlocuplumabC-X-C chemokine receptor type 4target
Von Willebrand factor humanCoagulation factor VIIItarget
Von Willebrand factor humanCollagen alpha-1(I) chaintarget
Von Willebrand factor humanA disintegrin and metalloproteinase with thrombospondin motifs 13enzyme
Von Willebrand factor humanAsialoglycoprotein receptor 1target
Von Willebrand factor humanProlow-density lipoprotein receptor-related protein 1target
Coagulation factor VII humanTissue factortarget
Coagulation factor VII humanCoagulation factor Xtarget
Coagulation factor VII humanCoagulation factor IXtarget
Anti-inhibitor coagulant complexCoagulation factor Xtarget
Anti-inhibitor coagulant complexProthrombintarget
Anti-inhibitor coagulant complexFibrinogen alpha chaintarget
Anti-inhibitor coagulant complexFibrinogen beta chaintarget
Anti-inhibitor coagulant complexCoagulation factor XIII A chaintarget
Anti-inhibitor coagulant complexCoagulation factor Vtarget
Anti-inhibitor coagulant complexCoagulation factor VIIItarget
Anti-inhibitor coagulant complexCoagulation factor VIItarget
Coagulation Factor IX HumanCoagulation factor Xtarget
Coagulation Factor IX HumanCoagulation factor XItarget
Coagulation Factor IX HumanCoagulation factor VIItarget
Coagulation Factor IX HumanCoagulation factor VIIItarget
Coagulation Factor IX HumanProthrombintarget
Coagulation Factor IX HumanProlow-density lipoprotein receptor-related protein 1target
Coagulation Factor IX HumanVitamin K-dependent gamma-carboxylasetarget
Antihemophilic factor humanCoagulation factor IXtarget
Antihemophilic factor humanCoagulation factor Xtarget
Antihemophilic factor humanVitamin K-dependent protein Cenzyme
Albutrepenonacog alfaCoagulation factor Xtarget
Albutrepenonacog alfaCoagulation factor VIIIenzyme
Nonacog beta pegolCoagulation factor VIItarget
Nonacog beta pegolCoagulation factor VIIItarget
Nonacog beta pegolCoagulation factor Xtarget
Moroctocog alfaCoagulation factor Xtarget
Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
Moroctocog alfaCoagulation factor IXtarget
Moroctocog alfaAsialoglycoprotein receptor 2target
Moroctocog alfa78 kDa glucose-regulated proteintarget
Moroctocog alfaCalreticulintarget
Moroctocog alfaCalnexintarget
Moroctocog alfaProtein ERGIC-53target
Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
Moroctocog alfaMultiple coagulation factor deficiency protein 2target
Moroctocog alfavon Willebrand factortarget
Moroctocog alfaProthrombinenzyme
Moroctocog alfaVitamin K-dependent protein Cenzyme
Andexanet alfaTissue factor pathway inhibitortarget
SutimlimabComplement C1s subcomponenttarget
ToripalimabProgrammed cell death protein 1target
ZilucoplanComplement C5target
Anti-SARS-CoV-2 REGN-COV2Spike glycoproteintarget
SintilimabProgrammed cell death protein 1target
EnvafolimabProgrammed cell death 1 ligand 1target
EtesevimabSpike glycoproteintarget
Rurioctocog alfa pegolvon Willebrand factortarget
Rurioctocog alfa pegolCoagulation factor VIIItarget
Loncastuximab tesirineB-lymphocyte antigen CD19target
Loncastuximab tesirineP-glycoprotein 1transporter
Loncastuximab tesirineCytochrome P450 3A4enzyme
Loncastuximab tesirineCytochrome P450 3A5enzyme
VilobelimabComplement C5target
NarsoplimabMannan-binding lectin serine protease 2target
BudigalimabProgrammed cell death protein 1target
Tisotumab vedotinCytochrome P450 3A4enzyme
Tisotumab vedotinTissue factortarget
Tisotumab vedotinP-glycoprotein 1transporter
PegdinetanibVascular endothelial growth factor receptor 2target
BebtelovimabSpike glycoproteintarget